P72

The impact of dysphagia in Parkinson's disease patients treated with levodopa/carbidopa intestinal gel

<u>Domiziana Rinaldi</u>^{1,2}, G. Imbalzano^{3,4}, S. Galli¹, E. Bianchini¹, C. Ledda^{3,4}, L. De Carolis¹, M. Zibetti^{3,4}, L. Lopiano^{3,4}, F.E. Pontieri^{1,2}, C.A. Artusi^{3,4}

¹Dipartimento di Neuroscienze, Salute Mentale e Organi di Senso, Sapienza Università di Roma, Rome, Italy

²Fondazione Santa Lucia, IRCCS, Rome, Italy

³Department of Neuroscience "Rita Levi Montalcini", University of Turin, Turin, Italy

⁴SC Neurologia 2U, AOU City of Health and Science, Turin, Italy

Background: Dysphagia is a common feature in advanced phases of Parkinson's disease (PD), representing a significant risk factor for aspiration pneumonia, which is the first cause of death in PD. The impact of dysphagia in advanced PD patients treated with levodopa-carbidopa intestinal gel (LCIG) has been poorly investigated.

Methods: We retrospectively evaluated data from 95 consecutive PD patients treated with LCIG in two Italian movement disorder centers. Kaplan-Meier survival analysis and log-rank test were used to compare the survival between patients developing dysphagia (LCIG-Dys) or not (LCIG-NDys). A Cox regression was used to estimate the influence of age, disease duration, Hoehn and Yahr (H&Y) at LCIG implantation, and presence of dysphagia on mortality. We used univariate and multivariate regression analysis to estimate the association between dysphagia and age, disease duration, H&Y, hallucinations, and dementia at last evaluation.

Results: The survival analysis showed a significant higher mortality in LCIG-Dys vs. LCIG-NDys group. Dysphagia was the only variable significantly associated with mortality (95%CI 2.780–20.609; p< 0.001). Univariate analyses showed a significant correlation between dysphagia and dementia (OR: 0.387; p: 0.033), hallucinations (OR: 0.283; p: 0.009), and H&Y score (OR: 2.680; p< 0.001). In the multivariate analysis, only the H&Y stage survived (OR: 2.357; p: 0.003).

Conclusions: Dysphagia significantly increased the risk of death in our cohort of LCIG-treated patients, independently from the presence of dementia and hallucinations. These findings confirm the management of this symptom as a priority in the advanced PD stages, especially in people treated with LCIG.